A review of methods for futility stopping based on conditional power - PubMed (original) (raw)
Review
. 2005 Sep 30;24(18):2747-64.
doi: 10.1002/sim.2151.
Affiliations
- PMID: 16134130
- DOI: 10.1002/sim.2151
Review
A review of methods for futility stopping based on conditional power
John M Lachin. Stat Med. 2005.
Abstract
Conditional power (CP) is the probability that the final study result will be statistically significant, given the data observed thus far and a specific assumption about the pattern of the data to be observed in the remainder of the study, such as assuming the original design effect, or the effect estimated from the current data, or under the null hypothesis. In many clinical trials, a CP computation at a pre-specified point in the study, such as mid-way, is used as the basis for early termination for futility when there is little evidence of a beneficial effect. Brownian motion can be used to describe the distribution of the interim Z-test value, the corresponding B-value, and the CP values under a specific assumption about the future data. A stopping boundary on the CP value specifies an equivalent boundary on the B-value from which the probability of stopping for futility can then be computed based on the planned study design (sample size and duration) and the assumed true effect size. This yields expressions for the total type I and II error probabilities. As the probability of stopping increases, the probability of a type I error alpha decreases from the nominal desired level (e.g. 0.05) while the probability of a type II error beta increases from the level specified in the study design. Thus a stopping boundary on the B-value can be determined such that the inflation in type II error probability is controlled at a desired level. An iterative procedure is also described that determines a stopping boundary on the B-value and a final test critical Z-value with specified type I and II error probabilities. The implementation in conjunction with a group sequential analysis for effectiveness is also described.
Copyright 2005 John Wiley & Sons, Ltd.
Similar articles
- Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM. Lachin JM. Clin Trials. 2009 Dec;6(6):565-73. doi: 10.1177/1740774509350327. Epub 2009 Nov 23. Clin Trials. 2009. PMID: 19933716 - Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM. Lachin JM. Stat Med. 2006 Oct 15;25(19):3348-65. doi: 10.1002/sim.2455. Stat Med. 2006. PMID: 16345019 - A composite design for transition from a preliminary to a full-scale study.
Lachin JM, Younes N. Lachin JM, et al. Stat Med. 2007 Nov 30;26(27):5014-32. doi: 10.1002/sim.2963. Stat Med. 2007. PMID: 17577245 - Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
Yi J, Fang L, Su Z. Yi J, et al. Contemp Clin Trials. 2012 Jan;33(1):138-42. doi: 10.1016/j.cct.2011.09.003. Epub 2011 Sep 29. Contemp Clin Trials. 2012. PMID: 21983624 Review. - Statistical reasoning in clinical trials: hypothesis testing.
Kelen GD, Brown CG, Ashton J. Kelen GD, et al. Am J Emerg Med. 1988 Jan;6(1):52-61. doi: 10.1016/0735-6757(88)90207-0. Am J Emerg Med. 1988. PMID: 3275456 Review.
Cited by
- Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review.
Lee SY. Lee SY. BMC Med Res Methodol. 2024 May 7;24(1):110. doi: 10.1186/s12874-024-02235-0. BMC Med Res Methodol. 2024. PMID: 38714936 Free PMC article. Review. - Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J, Li G, Yang D, Wu J, Wang J, Gao X, Liu P. Yang J, et al. BMC Med Res Methodol. 2024 Jan 17;24(1):12. doi: 10.1186/s12874-024-02144-2. BMC Med Res Methodol. 2024. PMID: 38233758 Free PMC article. Clinical Trial. - Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
Zocholl D, Kunz CU, Rauch G. Zocholl D, et al. Stat Methods Med Res. 2023 Sep;32(9):1749-1765. doi: 10.1177/09622802231188515. Epub 2023 Jul 25. Stat Methods Med Res. 2023. PMID: 37489267 Free PMC article. Clinical Trial. - Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.
Wang X, George SL. Wang X, et al. Clin Trials. 2023 Dec;20(6):603-612. doi: 10.1177/17407745231181908. Epub 2023 Jun 27. Clin Trials. 2023. PMID: 37366172 Free PMC article. - Recent innovations in adaptive trial designs: A review of design opportunities in translational research.
Kaizer AM, Belli HM, Ma Z, Nicklawsky AG, Roberts SC, Wild J, Wogu AF, Xiao M, Sabo RT. Kaizer AM, et al. J Clin Transl Sci. 2023 Apr 28;7(1):e125. doi: 10.1017/cts.2023.537. eCollection 2023. J Clin Transl Sci. 2023. PMID: 37313381 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous